NASDAQ:IMVT 20 May 2026

Roivant stock set for new test after big move on drug data
·····

Roivant stock set for new test after big move on drug data

Roivant Sciences shares rose 1.2% to $30.31 in light premarket trading Tuesday after last week’s 14% surge on positive IMVT-1402 drug data. Immunovant, developing the autoimmune drug, jumped 31% last week despite reporting a larger loss than expected. BofA raised its price target to $31.50 but kept a Neutral rating, while Citi and TD Cowen lifted targets and maintained Buy calls. U.S. markets reopened after the Memorial Day holiday.
May 26, 2026
ARGX Stock Watch: Argenx Up Ahead of Immunovant Trial Data
······

ARGX Stock Watch: Argenx Up Ahead of Immunovant Trial Data

argenx SE shares rose 0.7% to $803.67 Wednesday, trailing biotech peers after Immunovant reported positive rheumatoid arthritis trial data for IMVT-1402, sending its stock up 35.1%. VYVGART sales reached $1.3 billion last quarter. The FDA recently expanded VYVGART’s approval for generalized myasthenia gravis. argenx’s next key data releases are expected later this year.
May 20, 2026

Stock Market Today

  • XRO and WTC Shares: Key ASX Stock Insights and Performance Analysis
    May 28, 2026, 4:40 PM EDT. Xero Ltd (ASX:XRO) and WiseTech Global Ltd (ASX:WTC) are notable Australian Securities Exchange stocks to watch. Since 2025, XRO shares have fallen 33.6%, while WTC shares are 70% below their 52-week high. Xero, a cloud-based accounting software leader, grew revenues by 26.4% annually to $1.7 billion in FY24 with a net profit rise from -$9 million to $175 million and a 14.3% return on equity (ROE). WiseTech, specializing in logistics software, reported revenue growth of 27.1% yearly to $1.04 billion with net profit up from $108 million to $263 million and a 12.8% ROE. These fundamentals reflect significant growth but require further valuation context for investing decisions.